73496-31-8 Usage
Chemical Family
The compound belongs to the quinolinone family.
Core Structure
It has a quinolinone core structure.
Substitution
The compound has a methoxy group at the 7th position and a trifluoromethyl group at the 4th position.
Potential Pharmacological Properties
2(1H)-Quinolinone, 7-methoxy-4-(trifluoromethyl)has attracted attention in the field of medicinal chemistry due to its potential pharmacological properties.
Drug Development
The compound has been studied for its potential in drug development, particularly as a candidate for the treatment of various diseases.
Trifluoromethyl Group
The trifluoromethyl group in 2(1H)-Quinolinone, 7-methoxy-4-(trifluoromethyl)- has been investigated for its potential in medicinal chemistry, as it can enhance the biological activity of the molecule.
Further Research
Further research is needed to fully understand the pharmacological potential of 2(1H)-Quinolinone, 7-methoxy-4-(trifluoromethyl)and its potential applications in medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 73496-31-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,3,4,9 and 6 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 73496-31:
(7*7)+(6*3)+(5*4)+(4*9)+(3*6)+(2*3)+(1*1)=148
148 % 10 = 8
So 73496-31-8 is a valid CAS Registry Number.
73496-31-8Relevant academic research and scientific papers
Substituted benzolactam compounds
-
, (2008/06/13)
This invention relates to compounds of the general formula (1): or a pharmaceutically acceptable salt thereof, W, T, Y, X, Q, R1, R2, and R3 are defined herein. This invention also relates to compounds of the formula I, depicted above, wherein Y is —NH—; T is (2S,3S)-2-phenylpiperidin-3-yl, where the phenyl group of said (2S, 3S)-2-phenylpiperidine-3-yl may optionally be substituted with fluoro; Q is oxygen and is double bonded to the carbon atom to which it is attached, X is methoxy or ethoxy, R1 is hydrogen, methyl or halo-C1-C2 alkyl, W is methylene, ethylene or vinylene; R2 and R3 are independently hydrogen or methyl, or one of R2 or R3 may be hydroxy, when W is ethylene, R2 and R3 are both methyl, when W is methylene, and R2 and R3 are both hydrogen, when W is vinylene. The invention is further directed to methods of treating various CNS and other disorders using said compounds and pharmaceutical compositions thereof.
